# Harmony Biosciences Reports 16% WAKIX Revenue Growth in Q2 2025; Phase 3 Fragile X Readout on Track for Q3

> news · REPORTED · 2025-08-05

Harmony Biosciences announced 16 percent year-over-year revenue growth for WAKIX in Q2 2025 driven by 400 new patient adds, and confirmed that topline Phase 3 RECONNECT data for ZYN002 in Fragile X syndrome would be disclosed in Q3 2025. The company held over $672 million in cash as of the quarter end.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage neuroscience company that develops and markets WAKIX (pitolisant), a first-in-class H3 receptor antagonist approved for narcolepsy, alongside a pipeline of rare CNS disorder therapies.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-reports-strong-q2-2025-financial-results-and/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.